NCT05265052 - 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain | Biotech Hunter

Enrollment

177

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Cancer Pain

Interventions

DRUG

3D1002 (50 mg)(Phase IIa)

1 tablet of 3D1002 per oral dose

DRUG

3D1002 (100 mg)(Phase IIa)

2 tablets of 3D1002 per oral dose

DRUG

3D1002 (150 mg)(Phase IIa)

3 tablets of 3D1002 per oral dose

DRUG

3D1002 monotherapy (Phase IIb)

3D1002 is administered at recommended dose with mimic OxyContin tablets.

DRUG

OxyContin monotherapy (Phase IIb)

OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.

DRUG

3D1002 + OxyContin (Phase IIb)

3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.